A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2014
At a glance
- Drugs Finerenone (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ARTS-DN Japan
- Sponsors Bayer
- 01 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Oct 2014 Planned End Date changed from 1 Jan 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
- 02 Oct 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov record.